Repligen fails in Phase IIb depression study, shares slump
This article was originally published in Scrip
Executive Summary
Repligen's oral formulation of uridine, RG2417, has failed in a Phase IIb trial of bipolar depression, causing the company's share price to close at $3.54 on 7 March, a drop of nearly 28%.